Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a controlled‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when other analgesics are insufficient. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts within the central nervous system to relieve pain. - Chronic musculoskeletal pain: Provides sustained relief for conditions such as osteoarthritis and low‑back pain. - Neuropathic pain: Helps reduce pain associated with diabetic peripheral neuropathy. - Cancer‑related pain: Offers long‑acting analgesia for breakthrough pain in oncology patients.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Somnolence: increased sleepiness. - Headache: mild cranial discomfort. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: rare convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, or anaphylaxis. - Dependence or abuse potential: risk of misuse with prolonged use. - Adrenal insufficiency: rare hormonal imbalance.

When prescribing Tapentadol, clinicians should evaluate patient history and monitor for safety concerns. - Assess renal function: adjust use in severe impairment. - Evaluate hepatic function: caution in liver disease. - Review concomitant CNS depressants: increased sedation risk. - Monitor for signs of abuse: implement risk‑mitigation strategies. - Pregnancy and lactation: use only if clearly needed. - Store below 25°C: keep in the original container, protect from moisture and light.

Tapentadol interacts with several drug classes; careful review is essential.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - MAO‑inhibitors: risk of hypertensive crisis or serotonin syndrome.\n- Strong CYP2D6 inhibitors (e.g., fluoxetine): may increase tapentadol levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - Antihistamines: additive sedation. - Diuretics: may enhance hypotensive effects. - Alcohol: increases central nervous system depression.